-
Something wrong with this record ?
Long-term outcomes of intravenous fibrinolysis in central retinal artery occlusion
P. Kozner, L. Eichenmann, M. Ceska Burdova, M. Pavlikova, M. Hlozanek, D. Dotrelova
Language English Country England, Great Britain
Document type Observational Study, Journal Article
Grant support
00064203
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
Nature Open Access
from 2011-12-01
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Nature OA/Free Journals
from 2011-12-01
- MeSH
- Fibrin Clot Lysis Time MeSH
- Fibrinolysis * MeSH
- Administration, Intravenous MeSH
- Humans MeSH
- Retinal Artery Occlusion * drug therapy MeSH
- Thrombolytic Therapy adverse effects MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
Central retinal artery occlusion (CRAO) is an ophthalmologic emergency that can lead to irreversible loss of vision. Intravenous thrombolysis (IVT) has been used experimentally for its treatment. Our study aimed to evaluate the effect of emergency IVT on CRAO and its impact on visual acuity outcomes. We conducted a retrospective observational study of patients with CRAO. A total of 46 patients with CRAO were analysed; 16 patients received IVT treatment (IVT group) while 30 did not (no-IVT group). Seven patients from the IVT group received IVT early, within 4.5 hours (h) after the onset of symptoms (early-IVT), and 9 patients received it beyond this timeframe (late-IVT). The median time-to-hospital was 8.5 h: 3 h for the IVT group and 24 h for the no-IVT group. The median time-to-treatment was 5 h. The median outcome of visual acuity was 0.05 in the early-IVT, 0.025 in the late-IVT, and 0.01 in the no-IVT group. Among patients who received IVT early, 86% exhibited significant visual improvement. This improvement was four-fold greater compared to all other groups (p = 0.040), including the late-IVT (p = 0.011) and no-IVT groups (p = 0.023). No complications of the treatment were reported. Our study confirms that the administration of IVT treatment for CRAO within the 4.5-h time window is both safe and effective.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000629
- 003
- CZ-PrNML
- 005
- 20240213093307.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-023-47987-9 $2 doi
- 035 __
- $a (PubMed)37993533
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kozner, Pavel $u Department of Ophthalmology, Second Faculty of Medicine Charles University and Motol University Hospital in Prague, V Uvalu 84, 150 06, Prague, Czech Republic. pavel.kozner@fnmotol.cz
- 245 10
- $a Long-term outcomes of intravenous fibrinolysis in central retinal artery occlusion / $c P. Kozner, L. Eichenmann, M. Ceska Burdova, M. Pavlikova, M. Hlozanek, D. Dotrelova
- 520 9_
- $a Central retinal artery occlusion (CRAO) is an ophthalmologic emergency that can lead to irreversible loss of vision. Intravenous thrombolysis (IVT) has been used experimentally for its treatment. Our study aimed to evaluate the effect of emergency IVT on CRAO and its impact on visual acuity outcomes. We conducted a retrospective observational study of patients with CRAO. A total of 46 patients with CRAO were analysed; 16 patients received IVT treatment (IVT group) while 30 did not (no-IVT group). Seven patients from the IVT group received IVT early, within 4.5 hours (h) after the onset of symptoms (early-IVT), and 9 patients received it beyond this timeframe (late-IVT). The median time-to-hospital was 8.5 h: 3 h for the IVT group and 24 h for the no-IVT group. The median time-to-treatment was 5 h. The median outcome of visual acuity was 0.05 in the early-IVT, 0.025 in the late-IVT, and 0.01 in the no-IVT group. Among patients who received IVT early, 86% exhibited significant visual improvement. This improvement was four-fold greater compared to all other groups (p = 0.040), including the late-IVT (p = 0.011) and no-IVT groups (p = 0.023). No complications of the treatment were reported. Our study confirms that the administration of IVT treatment for CRAO within the 4.5-h time window is both safe and effective.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a fibrinolýza $7 D005342
- 650 _2
- $a trombolytická terapie $x škodlivé účinky $7 D015912
- 650 12
- $a okluze retinální arterie $x farmakoterapie $7 D015356
- 650 _2
- $a fibrinolytická aktivita $7 D063285
- 650 _2
- $a intravenózní podání $7 D061605
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Eichenmann, Libor $u Department of Ophthalmology, Second Faculty of Medicine Charles University and Motol University Hospital in Prague, V Uvalu 84, 150 06, Prague, Czech Republic
- 700 1_
- $a Ceska Burdova, Marie $u Department of Ophthalmology, Second Faculty of Medicine Charles University and Motol University Hospital in Prague, V Uvalu 84, 150 06, Prague, Czech Republic
- 700 1_
- $a Pavlikova, Marketa $u Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Hlozanek, Martin $u Department of Ophthalmology, Second Faculty of Medicine Charles University and Motol University Hospital in Prague, V Uvalu 84, 150 06, Prague, Czech Republic
- 700 1_
- $a Dotrelova, Dagmar $u Department of Ophthalmology, Second Faculty of Medicine Charles University and Motol University Hospital in Prague, V Uvalu 84, 150 06, Prague, Czech Republic
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 20505
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37993533 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093304 $b ABA008
- 999 __
- $a ok $b bmc $g 2049340 $s 1210323
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 13 $c 1 $d 20505 $e 20231122 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a 00064203 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20240109